Guardant Health Inc.(GH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GH Guardant Health Inc.

Not Yet Opened 12-20 16:00:00 EST

31.67

+0.54

+1.73%

盘后31.67

+0.00+0.00%

19:53 EST

High32.22	Low30.49	Vol2.41M
Open30.69	D1 Closing31.13	Amplitude5.56%
Mkt Cap3.91B	Tradable Cap3.31B	Total Shares123.55M
T/O76.49M	T/O Rate2.31%	Tradable Shares104.39M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"GH","market":"US","secType":"STK","nameCN":"Guardant Health Inc.","latestPrice":31.67,"timestamp":1734728400000,"preClose":31.13,"halted":0,"volume":2414320,"hourTrading":{"tag":"盘后","latestPrice":31.6705,"preClose":31.67,"latestTime":"19:53 EST","volume":337281,"amount":10681694.1685,"timestamp":1734742417580},"delay":0,"floatShares":104394677,"shares":123554612,"eps":-4.219128,"marketStatus":"Not Yet Opened","change":0.54,"latestTime":"12-20 16:00:00 EST","open":30.69,"high":32.22,"low":30.49,"amount":76492630.15616,"amplitude":0.055573,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.219128,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1734944400000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1538625600000,"exchange":"NASDAQ","adjPreClose":31.13,"preHourTrading":{"tag":"盘前","latestPrice":30.7,"preClose":31.13,"latestTime":"09:26 EST","volume":65,"amount":1975.553515,"timestamp":1734704781952},"postHourTrading":{"tag":"盘后","latestPrice":31.6705,"preClose":31.67,"latestTime":"19:53 EST","volume":337281,"amount":10681694.1685,"timestamp":1734742417580},"volumeRatio":1.4659548331869443,"impliedVol":0.6554,"impliedVolPercentile":0.3373},"requestUrl":"/m/hq/s/GH/wiki","defaultTab":"wiki","newsList":[{"id":"2492435014","title":"Guardant Health enters partnership with MiBA","url":"https://stock-news.laohu8.com/highlight/detail?id=2492435014","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492435014?lang=en_us&edition=fundamental","pubTime":"2024-12-20 21:15","pubTimestamp":1734700530,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) and Meaningful Insights Biotech Analytics, or MiBA announced a partnership aimed at optimizing the use of biomarker testing an...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-health-enters-partnership-with-miba?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-health-enters-partnership-with-miba?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4551","GH","BK4196","BK4535","BK4585"],"gpt_icon":0},{"id":"2492288448","title":"Meaningful Insights Biotech Analytics (MiBA) and Guardant Health Announce Strategic Partnership to Optimize Use of Biomarker Testing and Data Analytics to Improve Cancer Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2492288448","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492288448?lang=en_us&edition=fundamental","pubTime":"2024-12-20 21:05","pubTimestamp":1734699900,"startTime":"0","endTime":"0","summary":"PALO ALTO, Calif. & TAMPA, Fla., December 20, 2024----Guardant Health, Inc. , a leading precision oncology company, and Meaningful Insights Biotech Analytics , an innovative healthcare technology company, today announced a unique partnership aimed at optimizing the use of biomarker testing and data analytics to advance precision medicine in patient care throughout the MiBA Network.Recognizing the evolving landscape of precision medicine, the collaboration combines MiBA's cutting-edge artificial intelligence  technologies and high-quality oncology data with Guardant's expertise in comprehensive tumor profiling and circulating tumor DNA  monitoring. Together, the companies aim to transform cancer care by driving personalized, data-driven approaches that facilitate broad, consistent access to innovative treatments that can enhance patient outcomes.\"Precision oncology is redefining cancer treatment, enabling more tailored treatment through the use of biomarkers and monitoring of circulatin","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/j6kJKzYhy0agHml.CWW3kQ--~B/aD02MTk7dz0xODA2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/63d8da142e0bbc86f039d5ab2320da8a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/j6kJKzYhy0agHml.CWW3kQ--~B/aD02MTk7dz0xODA2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/63d8da142e0bbc86f039d5ab2320da8a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/meaningful-insights-biotech-analytics-miba-130500989.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","GH","BK4551","BK4535","BK4196","BK4588"],"gpt_icon":0},{"id":"2492103411","title":"Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)","url":"https://stock-news.laohu8.com/highlight/detail?id=2492103411","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492103411?lang=en_us&edition=fundamental","pubTime":"2024-12-20 19:50","pubTimestamp":1734695400,"startTime":"0","endTime":"0","summary":"Acquisition bolsters Eton’s commercial pediatric endocrinology portfolioProduct is now available through AnovoRx, a specialty pharmacy dedicated to serving patients with rare and chronic conditions DE","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/20/3000471/0/en/Eton-Pharmaceuticals-Closes-Acquisition-of-Increlex-mecasermin-injection.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4551","GH","BK4196","BK4156","BK4588","BK4535"],"gpt_icon":0},{"id":"2492772108","title":"Guardant Health, COTA Collaborate to Provide Combined Data for Cancer Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2492772108","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492772108?lang=en_us&edition=fundamental","pubTime":"2024-12-20 00:06","pubTimestamp":1734624416,"startTime":"0","endTime":"0","summary":"Guardant Health  and COTA are collaborating to help biopharmaceutical researchers access COTA's electronic health record data and Guardant's clinicogenomic testing data to speed up the development of new cancer treatments, COTA said Thursday.The partnership expands COTA's data, particularly in lung, breast, and colorectal cancers, creating a larger, more diverse dataset with significant patient overlap to provide better clinical insights, COTA said.Price: 31.87, Change: -0.50, Percent Change: -1.53","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4551","BK4535","GH","BK4196","BK4585"],"gpt_icon":0},{"id":"2492280541","title":"Cota and Guardant Health Partner to Advance Precision Oncology Research and Therapy Development With Real-World Clinicogenomic Data and AI Analytics","url":"https://stock-news.laohu8.com/highlight/detail?id=2492280541","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492280541?lang=en_us&edition=fundamental","pubTime":"2024-12-19 19:00","pubTimestamp":1734606003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nTUA38PJKF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4551","BK4535","BK4588","BK4196","BK4585","GH"],"gpt_icon":0},{"id":"2492125588","title":"COTA and Guardant Health Partner to Advance Precision Oncology Research and Therapy Development with Real-World Clinicogenomic Data and AI Analytics","url":"https://stock-news.laohu8.com/highlight/detail?id=2492125588","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492125588?lang=en_us&edition=fundamental","pubTime":"2024-12-19 19:00","pubTimestamp":1734606000,"startTime":"0","endTime":"0","summary":"NEW YORK, December 19, 2024----COTA Inc., a leader in real-world data  and analytics for oncology, announces a new partnership with leading precision oncology company Guardant Health Inc.  that will allow biopharmaceutical researchers to access the combined resources of COTA’s research-grade electronic health record  data from academic and community care centers and Guardant’s clinicogenomic testing data to accelerate the development of new cancer therapies.Guardant’s extensive real-world longitudinal serial testing datasets span all stages of the disease, from initial tumor profiling for therapy selection to recurrence and therapy response monitoring, while COTA’s highly curated data tracks a patient’s complete cancer care journey, drawing from both academic and community care center settings. This new collaboration with Guardant deepens COTA’s data by expanding its breadth into solid tumors, particularly lung, breast, and colorectal cancers, creating a broader, more diverse data se","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/C.esJ.cK8ex9Io7SYysfhw--~B/aD0zNDU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/502ce5b84e5448cf1210d3f362e2cd6d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/C.esJ.cK8ex9Io7SYysfhw--~B/aD0zNDU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/502ce5b84e5448cf1210d3f362e2cd6d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cota-guardant-health-partner-advance-110000908.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"COTA and Guardant Health Partner to Advance Precision Oncology Research and Therapy Development with Real-World Clinicogenomic Data and AI Analytics","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4535","GH","BK4551","BK4196","BK4588","BK4585"],"gpt_icon":0},{"id":"2492144186","title":"Guardant Health, Boehringer Collaborate on Companion Test for Potential Lung Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2492144186","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492144186?lang=en_us&edition=fundamental","pubTime":"2024-12-18 21:59","pubTimestamp":1734530387,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) said Wednesday that it is collaborating with German pharmaceutical company Boehringer Ingelheim to seek regulatory approval and commercialize Guardant360 CDx liquid biopsy test as","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4551","BK4585","BK4535","BK4588","GH","BK4196"],"gpt_icon":0},{"id":"2492718809","title":"Guardant Health Announces Collaboration With Boehringer Ingelheim to Develop Companion Diagnostic for Detection of Specific Mutations in Advanced Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2492718809","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492718809?lang=en_us&edition=fundamental","pubTime":"2024-12-18 21:05","pubTimestamp":1734527100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUAGHNQF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4535","GH","BK4551","BK4196","BK4588","BK4585"],"gpt_icon":0},{"id":"2492885184","title":"Guardant Health Announces Collaboration With Boehringer Ingelheim to Develop Companion Diagnostic for Detection of Specific Mutations in Advanced Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2492885184","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492885184?lang=en_us&edition=fundamental","pubTime":"2024-12-18 21:05","pubTimestamp":1734527100,"startTime":"0","endTime":"0","summary":"PALO ALTO, Calif., December 18, 2024----Guardant Health, Inc. , a leading precision oncology company, today announced a collaboration with Boehringer Ingelheim to pursue the regulatory approval and commercialization of the Guardant360 CDx liquid biopsy as a companion diagnostic  for zongertinib, an investigational covalent tyrosine kinase inhibitor  that selectively inhibits HER2 while sparing epidermal growth factor receptor  in non-small cell lung cancer .As part of the collaboration, the Guardant360 CDx blood test will provide comprehensive genomic profiling  of tumors to identify actionable biomarkers that allow targeted therapy selection and help identify NSCLC patients with HER2 mutations who may be eligible for treatment with Boehringer’s investigational zongertinib after it is approved by health authorities.\"Many of the 40,000 people diagnosed worldwide every year with NSCLC with a HER2 mutation may respond poorly to standard chemotherapy and immunotherapy,\" said Helmy Eltoukhy","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/3AVl.t5fmMaDpjIVxpKDlw--~B/aD02MTk7dz0xODA2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/be94b5ef5af93bca645d29aa5e425ab3","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/3AVl.t5fmMaDpjIVxpKDlw--~B/aD02MTk7dz0xODA2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/be94b5ef5af93bca645d29aa5e425ab3"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/guardant-health-announces-collaboration-boehringer-130500936.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4551","BK4585","GH","IE0031619046.USD","IE00B19Z4B17.USD","BK4196","BK4535","BK4157","IE00B7SZL793.SGD","IE00B66KJ199.SGD","AEIS"],"gpt_icon":0},{"id":"2490861453","title":"Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures’ Acquisition of Lumos Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2490861453","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490861453?lang=en_us&edition=fundamental","pubTime":"2024-12-12 21:47","pubTimestamp":1734011220,"startTime":"0","endTime":"0","summary":"AUSTIN, Texas and GREENWICH, Conn., Dec.  12, 2024  (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO) (“Lumos Pharma” or the “Company”), a clinical stage biopharmaceutical company focused on therap","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/12/2996226/15114/en/Lumos-Pharma-and-Double-Point-Ventures-Announce-Successful-Completion-of-Tender-Offer-and-Double-Point-Ventures-Acquisition-of-Lumos-Pharma.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4551","BK4139","GH","BK4535","LUMO","BK4196","BK4588"],"gpt_icon":0},{"id":"2490472746","title":"Guardant Health to Share New Research Demonstrating Value of Liquid Biopsy Tests, Real-world Data and AI Analytics in Tailoring Treatment Approaches for Breast Cancer at 2024 San Antonio Breast Cancer Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2490472746","media":"Business Wire","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490472746?lang=en_us&edition=fundamental","pubTime":"2024-12-09 21:05","pubTimestamp":1733749500,"startTime":"0","endTime":"0","summary":"Spotlight presentation using Guardant Reveal test suggests ctDNA has potential to predict sensitivity to endocrine therapy and long-term outcomes in HR+ breast cancer. PALO ALTO, Calif., December 09, 2024----Guardant Health, Inc. , a leading precision oncology company, today announced the company and its research collaborators will present data demonstrating the benefits of its precision oncology tests, real-world clinical-genomic database and AI analytics in optimizing therapy selection, identifying resistance mutations, and predicting long-term outcomes at the San Antonio Breast Cancer Symposium  2024 in San Antonio, Texas, Dec. 10-13, 2024.Guardant and its research partners will present eight posters, including an SABCS Poster Spotlight featuring the use of the Guardant Reveal test, a tissue-free epigenomic assay, to investigate the dynamics of circulating tumor DNA  during neoadjuvant endocrine therapy in HR+ early breast cancer. Study findings suggest that ctDNA has the potential ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/8SQmLgl_3.7lWangP4z3yw--~B/aD02MTk7dz0xODA2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/cbe8e45b5a79dd4ab4455e64086d3339","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/8SQmLgl_3.7lWangP4z3yw--~B/aD02MTk7dz0xODA2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/cbe8e45b5a79dd4ab4455e64086d3339"],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/guardant-health-share-research-demonstrating-130500353.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GH"],"gpt_icon":0},{"id":"2490995724","title":"Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly","url":"https://stock-news.laohu8.com/highlight/detail?id=2490995724","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490995724?lang=en_us&edition=fundamental","pubTime":"2024-12-09 21:00","pubTimestamp":1733749200,"startTime":"0","endTime":"0","summary":"FDA Assigns a Prescription Drug User Fee Act Target Action Date of September 25, 2025. SAN DIEGO, Dec. 09, 2024  -- Crinetics Pharmaceuticals, Inc.  today announced the U.S. Food and Drug Administration  accepted its New Drug Application  for investigational candidate paltusotine for the treatment and long-term maintenance therapy of acromegaly in adults. If approved, paltusotine will be the first and only once-daily, oral, selective somatostatin receptor type 2 nonpeptide agonist available for adults living with acromegaly.Paltusotine was granted Orphan Drug Designation for the treatment of acromegaly by the FDA in July 2020. This designation is provided to drugs defined as being intended for the safe and effective treatment, diagnosis or prevention of rare diseases that affect fewer than 200,000 people in the United States.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/C6YwZtvzo__JBt8F.ZtO3g--~B/aD0yNzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/7629089790345d42d3f8b783f2c3ed55","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/C6YwZtvzo__JBt8F.ZtO3g--~B/aD0yNzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/7629089790345d42d3f8b783f2c3ed55"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/crinetics-announces-fda-acceptance-drug-130000241.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4535","CRNX","GH","BK4196","BK4551","BK4588","BK4585"],"gpt_icon":0},{"id":"2489634514","title":"Investors in Guardant Health (NASDAQ:GH) from three years ago are still down 61%, even after 8.6% gain this past week","url":"https://stock-news.laohu8.com/highlight/detail?id=2489634514","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489634514?lang=en_us&edition=fundamental","pubTime":"2024-12-05 22:46","pubTimestamp":1733410007,"startTime":"0","endTime":"0","summary":"Over the last month the Guardant Health, Inc.  has been much stronger than before, rebounding by 61%. But over the last three years we've seen a quite serious decline. Tragically, the share price declined 61% in that time. So it's good to see it climbing back up. After all, could be that the fall was overdone.While the stock has risen 8.6% in the past week but long term shareholders are still in the red, let's see what the fundamentals can tell us.Over three years, Guardant Health grew revenue at 22% per year. That's well above most other pre-profit companies. The share price has moved in quite the opposite direction, down 17% over that time, a bad result. This could mean hype has come out of the stock because the losses are concerning investors. When we see revenue growth, paired with a falling share price, we can't help wonder if there is an opportunity for those who are willing to dig deeper.Please note, the market returns quoted in this article reflect the market weighted average r","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vXkHD.3TwJWHn8.mBhsrQg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/0fc6188304291c4515eba03ba128db49","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vXkHD.3TwJWHn8.mBhsrQg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/0fc6188304291c4515eba03ba128db49"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/investors-guardant-health-nasdaq-gh-144647875.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SQQQ","BK4551","IE00BKPKM429.USD","IE00BGHQF748.EUR","LU2210150020.SGD","IE00B64PRP62.GBP","TQQQ",".IXIC","BK4196","NDAQ","QID","GH","NQmain","BK4112","IE00B3QW5Z07.USD","MNQmain","BK4211","ISBC","LU2210149790.SGD","LU2095319765.USD","PSQ","QLD","BK4535","BK4585","BK4588"],"gpt_icon":1},{"id":"2489539264","title":"GH Research PLC Attends Key Neuropsychopharmacology Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2489539264","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489539264?lang=en_us&edition=fundamental","pubTime":"2024-12-05 20:27","pubTimestamp":1733401651,"startTime":"0","endTime":"0","summary":"GH Research (GHRS) has released an update. GH Research PLC is set to participate in the 63rd Annual Meeting of the American College of Neuropsychop...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gh-research-plc-attends-key-neuropsychopharmacology-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gh-research-plc-attends-key-neuropsychopharmacology-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","GH","BK4007","BK4551","BK4196","BK4535","BK4585","BK4588","GHRS"],"gpt_icon":0},{"id":"2486617630","title":"Jury Awards Guardant Health $292.5M in False-Advertising Lawsuit Against Natera","url":"https://stock-news.laohu8.com/highlight/detail?id=2486617630","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486617630?lang=en_us&edition=fundamental","pubTime":"2024-11-26 06:45","pubTimestamp":1732574700,"startTime":"0","endTime":"0","summary":"A jury awarded Guardant Health $292.5 million in damages related to a false-advertising and unfair-competition lawsuit that the oncology company brought against rival Natera in 2021.The decision, which includes $175.5 million in punitive damages, represents what Guardant Health on Monday called one of the largest false advertising verdicts in history.The jury found that Austin, Texas-based Natera engaged in a deliberate campaign to mislead cancer clinicians about Guardant Reveal, the Palo Alto, Calif., company's early-stage colorectal cancer test, in favor of Natera's competing product.Natera said it disagrees with the jury's decision and will ask the court to overturn it.\"The jury was asked to evaluate comparative advertisements that ran for a brief period in 2021 related to the performance of Guardant's Reveal test,\" the company said. \"This case had nothing to do with the validity or utility of Signatera and certain key pieces of evidence supporting Natera's case were not included in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH","NTRA","BK4139","BK4551","LU0053671581.USD","BK4196","LU2065170008.USD","LU2065171402.SGD","BK4535","LU2065169927.USD","BK4585","BK4588","LU2065171311.SGD","LU2065731478.USD"],"gpt_icon":0},{"id":"2486696550","title":"Guardant says jury unanimously found in favor of company in Natera suit","url":"https://stock-news.laohu8.com/highlight/detail?id=2486696550","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486696550?lang=en_us&edition=fundamental","pubTime":"2024-11-26 06:15","pubTimestamp":1732572907,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) announced that a jury in the U.S. District Court for the Northern District of California unanimously found in favor of Guardan...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-says-jury-unanimously-found-in-favor-of-company-in-natera-suit?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-says-jury-unanimously-found-in-favor-of-company-in-natera-suit?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4551","BK4535","LU2065171311.SGD","BK4588","LU2065171402.SGD","LU0053671581.USD","LU2065731478.USD","LU2065170008.USD","BK4196","LU2065169927.USD","BK4585","NTRA","GH"],"gpt_icon":0},{"id":"2486069969","title":"Federal Court Jury Issues Unanimous Verdict that Natera Engaged in False Advertising and Unfair Competition in Deliberate Attempt to Damage Guardant Health's Colorectal Cancer Test, Guardant Reveal™","url":"https://stock-news.laohu8.com/highlight/detail?id=2486069969","media":"PR Newswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486069969?lang=en_us&edition=fundamental","pubTime":"2024-11-26 06:09","pubTimestamp":1732572540,"startTime":"0","endTime":"0","summary":"Guardant Health Secures One of the Largest False Advertising Verdicts in History, Representing aSignificant Victory for Colorectal Cancer Patients Who Could Benefit from Guardant Reveal. Natera Found to Have Willfully Misled Oncologists in an Effort to Thwart Competition. The jury found that Natera engaged in a deliberate campaign to mislead cancer clinicians about Guardant Reveal – Guardant Health's tissue-free minimal residual disease  test for early-stage colorectal cancer  – in favor of Signatera, Natera's competing product.\"Today's unanimous verdict holding Natera responsible for engaging in illegal and anticompetitive conduct represents a major victory for CRC patients who could benefit from our groundbreaking Reveal test, and we thank the jury and the Court for their careful consideration of our claims,\" said John Saia, Chief Legal Officer at Guardant Health. \"Every company in the cancer diagnostics space has a duty to prioritize patients above all else. In keeping with our miss","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/75KK9xvk7aFUGhezsojHMA--~B/aD0yMjU7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/60919769b5e7f11f745bb8ce40a698d1","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/75KK9xvk7aFUGhezsojHMA--~B/aD0yMjU7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/60919769b5e7f11f745bb8ce40a698d1"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/federal-court-jury-issues-unanimous-220900862.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/federal-court-jury-issues-unanimous-220900862.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GH","CRC","LU0266512127.USD","US3Y.BOND","US12M.BOND","BK4588","NTRA","US30Y.BOND","BK4535","BK4585","LU2065731478.USD","LU2065169927.USD","BK4551","BK4139","US6M.BOND","BK4196","US5Y.BOND","US10Y.BOND","LU0456854461.SGD","US2Y.BOND","LU2065170008.USD","LU2065171402.SGD","BK4213","US7Y.BOND","LU2065171311.SGD","LU0053671581.USD"],"gpt_icon":0},{"id":"2486050132","title":"Natera ‘disagrees’ with jury’s decision in Guardant Health litigation","url":"https://stock-news.laohu8.com/highlight/detail?id=2486050132","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486050132?lang=en_us&edition=fundamental","pubTime":"2024-11-26 04:55","pubTimestamp":1732568106,"startTime":"0","endTime":"0","summary":"Natera (NTRA) issued the following statement: “In 2021, Natera and Guardant Health (GH) filed false advertising cases against each other concerning...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/natera-disagrees-with-jurys-decision-in-guardant-health-litigation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/natera-disagrees-with-jurys-decision-in-guardant-health-litigation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4551","LU0053671581.USD","BK4196","BK4139","BK4535","GH","LU2065169927.USD","LU2065170008.USD","LU2065171311.SGD","BK4588","BK4585","LU2065731478.USD","NTRA","LU2065171402.SGD"],"gpt_icon":0},{"id":"2486870050","title":"Guardant Health gains amid $292.5M verdict against Natera over false advertising claims","url":"https://stock-news.laohu8.com/highlight/detail?id=2486870050","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486870050?lang=en_us&edition=fundamental","pubTime":"2024-11-26 04:48","pubTimestamp":1732567716,"startTime":"0","endTime":"0","summary":"RossHelen/iStock via Getty Images Guardant Health  rose 8.7% at least partly after a North California jury awarded the company $292.5 million in a false advertising lawsuit against Natera  over Guardant's Reveal oncology test. Natera fell 2.3%. News of the jury verdict was first reported by Law360 on Monday. Guardant  filed the lawsuit in May 2021 against Natera for false advertising, unfair competition and unlawful trade practices relating to alleged misleading statements Natera made about the performance the Guardant Reveal oncology test. Natera  and Guardant Health  didn't immediately respond to Seeking Alpha email request for comment.","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/946264212/image_946264212.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/946264212/image_946264212.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4332231-guardant-health-gains-amid-2925m-verdict-against-natera-over-false-advertising-claims","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4585","BK4551","GH","BK4535","BK4196","BK4588"],"gpt_icon":0},{"id":"2485207129","title":"Guardant Health, Inc. (GH): Among the Most Promising Cancer Stocks According to Hedge Funds","url":"https://stock-news.laohu8.com/highlight/detail?id=2485207129","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485207129?lang=en_us&edition=fundamental","pubTime":"2024-11-23 23:29","pubTimestamp":1732375770,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Most Promising Cancer Stocks According to Hedge Funds.In this article, we are going to take a look at where Guardant Health, Inc.  stands against the other promising cancer stocks.According to the World Health Organization , cancer remains one of the leading causes of death globally, responsible for nearly 10 million deaths in 2020, or about one in six deaths worldwide. Moreover, the World Cancer Research Fund reports that approximately 18.1 million cancer cases were diagnosed that year, with the age-standardized rate, when considering all cancers except non-melanoma skin cancer and combining data for both men and women, came in at 190 cases per 100,000 individuals. This rate was notably higher in men, with 206.9 cases per 100,000, compared to 178.1 per 100,000 in women.Since there is no universal cure for cancer, developing a drug capable of treating multiple cancer types is incredibly lucrative. This dynamic fuels continuous breakthroughs in the ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/qPSqdNpSDK2UXRwU6g0kyw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/2a5225bbb1b6e607d0c46f4a4303fa02","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/qPSqdNpSDK2UXRwU6g0kyw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/2a5225bbb1b6e607d0c46f4a4303fa02"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/guardant-health-inc-gh-among-152930936.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4551","BK4159","BK4585","NQmain","PSQ","SQQQ","MNQmain","GH","BK4535","QLD","TQQQ","BK4196","BK4588","QID","CAGR",".IXIC"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.guardanthealth.com","stockEarnings":[{"period":"1week","weight":-0.0889},{"period":"1month","weight":0.0323},{"period":"3month","weight":0.2623},{"period":"6month","weight":0.0714},{"period":"1year","weight":0.1601},{"period":"ytd","weight":0.1708}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.014262},{"month":2,"riseRate":0.333333,"avgChangeRate":0.090686},{"month":3,"riseRate":0.5,"avgChangeRate":-0.027891},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.038707},{"month":5,"riseRate":0.666667,"avgChangeRate":0.099696},{"month":6,"riseRate":0.666667,"avgChangeRate":0.048686},{"month":7,"riseRate":0.833333,"avgChangeRate":0.095469},{"month":8,"riseRate":0.5,"avgChangeRate":-0.010162},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.064584},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.046039},{"month":11,"riseRate":0.714286,"avgChangeRate":0.125409},{"month":12,"riseRate":0.571429,"avgChangeRate":-0.06323}],"exchange":"NASDAQ","name":"Guardant Health Inc.","nameEN":"Guardant Health Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Guardant Health Inc.(GH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Guardant Health Inc.(GH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Guardant Health Inc.,GH,Guardant Health Inc.股票,Guardant Health Inc.股票老虎,Guardant Health Inc.股票老虎国际,Guardant Health Inc.行情,Guardant Health Inc.股票行情,Guardant Health Inc.股价,Guardant Health Inc.股市,Guardant Health Inc.股票价格,Guardant Health Inc.股票交易,Guardant Health Inc.股票购买,Guardant Health Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Guardant Health Inc.(GH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Guardant Health Inc.(GH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}